Clinical Trials Logo

ERBB2 Gene Mutation clinical trials

View clinical trials related to ERBB2 Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03066206 Active, not recruiting - Clinical trials for Recurrent Lung Non-Small Cell Carcinoma

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Start date: March 17, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..

NCT ID: NCT03065387 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Start date: October 31, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of neratinib in combination with everolimus, palbociclib, or trametinib in participants with solid tumors with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation, or KRAS mutation that do not respond to treatment (refractory) and have spread to other parts of the body (advanced or metastatic). Neratinib, palbociclib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving neratinib with everolimus, palbociclib, or trametinib may work better than neratinib alone in treating participants with solid tumors.